Research programme: diarrhoea therapies - Novartis/OneWorld Health

Drug Profile

Research programme: diarrhoea therapies - Novartis/OneWorld Health

Latest Information Update: 23 May 2012

Price : $50

At a glance

  • Originator Institute for OneWorld Health; Novartis
  • Class
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Research Diarrhoea

Most Recent Events

  • 23 May 2012 Early research is ongoing in USA
  • 15 Jul 2009 Early research in Diarrhoea in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top